Selwyn Spangenthal, MD
Pulmonary Disease · Charlotte, NCNPI 1710975297
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,340 of the $69,593 with a category attached, or 60.8%. 27 manufacturers reported payments, led by Mylan Specialty L.p. at 34.2% of the total. Reporting peaked in 2019 at $54,018 and has fallen 99.3% since, to $359 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $235.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$24K
- Boehringer Ingelheim$15K
- Sunovion Pharmaceuticals Inc.$12K
- GSK$9K
- AstraZeneca$2K
- Merck$2K
- plus $5K from 21 others
Across 677 payments — averaging $10,215 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$3.1M
- Genentech, Inc.$681K
- AstraZeneca$636K
- Verona Pharma, Inc.$487K
- GSK$486K
- Novartis$365K
- plus $1.2M from 23 others
What the payments were for
- Consulting fees$9,98714%
- Speaking & faculty fees$42,34061%
- Travel & lodging$10,80816%
- Food & beverage$6,3829%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 81 | $23,807 |
| Boehringer Ingelheim | 32 | $14,817 |
| Sunovion Pharmaceuticals Inc. | 28 | $12,388 |
| GSK | 41 | $9,383 |
| AstraZeneca | 36 | $2,351 |
| Merck | 11 | $2,090 |
| Astrazeneca UK Limited | 13 | $2,054 |
| Shionogi Inc | 9 | $1,119 |
| Novartis | 5 | $563 |
| Regeneron Healthcare Solutions, Inc. | 7 | $287 |
| Verona Pharma, Inc. | 4 | $153 |
| Sanofi | 3 | $130 |
| Insmed, Inc. | 3 | $78 |
| Circassia Inc. | 5 | $70 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Philips North America LLC | 2 | $36 |
| Masimo Corporation | 1 | $31 |
| Advanced Respiratory, Inc | 2 | $26 |
| Electromed, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Pfizer | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Breathe Technologies, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$22,554
- LONHALA MAGNAIR$12,129
- TRELEGY ELLIPTA$7,600
- FASENRA$2,901
- MK-7264$1,703
- OFEV$1,543
- ANORO$1,126
- DUPIXENT$125
- TEZSPIRE$121
- QBW251$109
- Ohtuvayre$108
How this compares
$69,593 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $111,260 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $29,049 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $23,120 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $22,765 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $12,208 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,630 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $5,303 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $4,285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 136 | $2,683 |
| Xopenex HfaLevalbuterol Tartrate | 14 | $2,041 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,843 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 16 | $1,345 |
| Omeprazole | 43 | $918 |
| Ventolin HfaAlbuterol Sulfate | 11 | $613 |
| Pantoprazole Sodium | 18 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $9,383 | $163,430264 claims |
| AstraZenecaBreztri Aerosphere | $2,351 | $22,76531 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $14,817 | $19,83938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Charlotte
- Jaspal SinghCharlotte$191K
- Muhammad RashadCharlotte$14K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.